Gene, SNP | Cohort | Year | Model | No. Patients | Estimate | Lo95 | Up95 | p |
---|---|---|---|---|---|---|---|---|
TRAF1/C5 rs2900180 | ERAS | 2 | ZINB severity | 356 | 0.42 | 0.05 | 0.93 | 0.025 |
ZINB susceptibility | 0.66 | 0.32 | 1.39 | 0.276 | ||||
NBREG | 192 | 0.32 | −0.04 | 0.81 | 0.092 | |||
LOGIT | 435 | 1.12 | 0.76 | 1.64 | 0.574 | |||
3 | ZINB severity | 353 | 0.31 | 0.04 | 0.65 | 0.024 | ||
ZINB susceptibility | 1.14 | 0.58 | 2.24 | 0.700 | ||||
NBREG | 224 | 0.43 | 0.12 | 0.81 | 0.004 | |||
LOGIT | 424 | 0.86 | 0.57 | 1.29 | 0.467 | |||
TRAF1/C5 rs10760130 | ERAS | 2 | ZINB severity | 356 | 0.41 | 0.03 | 0.92 | 0.030 |
ZINB susceptibility | 0.64 | 0.28 | 1.49 | 0.303 | ||||
NBREG | 192 | 0.36 | −0.02 | 0.88 | 0.069 | |||
LOGIT | 435 | 1.29 | 0.85 | 1.96 | 0.223 | |||
3 | ZINB severity | 353 | 0.32 | 0.02 | 0.69 | 0.032 | ||
ZINB susceptibility | 1.08 | 0.52 | 2.26 | 0.832 | ||||
NBREG | 224 | 0.30 | 0.01 | 0.68 | 0.046 | |||
LOGIT | 424 | 1.08 | 0.70 | 1.67 | 0.716 | |||
TRAF1/C5 rs2900180 | NOAR | 5 | ZINB severity | 608 | 0.15 | −0.08 | 0.43 | 0.223 |
ZINB susceptibility | 1.88 | 1.11 | 3.19 | 0.020 | ||||
NBREG | 267 | 0.06 | −0.12 | 0.27 | 0.558 | |||
LOGIT | 611 | 1.53 | 1.10 | 2.12 | 0.012 | |||
TRAF1/C5 rs10760130 | NOAR | 5 | ZINB severity | 607 | 0.18 | −0.07 | 0.50 | 0.165 |
ZINB susceptibility | 1.11 | 0.64 | 1.92 | 0.707 | ||||
NBREG | 266 | 0.07 | −0.12 | 0.30 | 0.513 | |||
LOGIT | 610 | 1.29 | 0.91 | 1.83 | 0.149 |
NOAR: Norfolk Arthritis Register; ERAS: Early Rheumatoid Arthritis Study; SNP: single-nucleotide polymorphism; Estimate: percentage increase in Larsen score for the severity part of the ZINB model and for the NBREG model, and OR for the susceptibility part of the ZINB model and for the LOGIT model; Lo95: lower 95% CI of the point estimate; Up95: upper 95% CI of the point estimate.